Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
Alpha Cognition announced the USPTO published its U.S. Patent Application No. 19/090,242 covering its proprietary manufacturing process for benzgalantamine, the active ingredient in ZUNVEYL. The application claims innovations in manufacturing efficiency, impurity control, and commercial-scale production of high-purity benzgalantamine.
Key figures
- Drug Name
- ZUNVEYL (benzgalantamine)
- Publication date
- October 1, 2026
- Publication number
- US 2026/0297103 A1
- Patent application number
- 19/090,242
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.